Fraser, G. Et Al. 2020. Final 5-year updated results from a phase 3 study (HELIOS) of ibrutinib plus bendamustine and rituximab (BR) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). LEUKEMIA & LYMPHOMA , vol.61 , 106-108.

Fraser, G., Chanan-Khan, A., Demirkan, F., Silva, R. S., Grosicki, S., Janssens, A., ... Mayer, J.(2020). Final 5-year updated results from a phase 3 study (HELIOS) of ibrutinib plus bendamustine and rituximab (BR) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). LEUKEMIA & LYMPHOMA , vol.61, 106-108.

Fraser, Graeme Et Al. "Final 5-year updated results from a phase 3 study (HELIOS) of ibrutinib plus bendamustine and rituximab (BR) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)," LEUKEMIA & LYMPHOMA , vol.61, 106-108, 2020

Fraser, Graeme Et Al. "Final 5-year updated results from a phase 3 study (HELIOS) of ibrutinib plus bendamustine and rituximab (BR) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)." LEUKEMIA & LYMPHOMA , vol.61, pp.106-108, 2020

Fraser, G. Et Al. (2020) . "Final 5-year updated results from a phase 3 study (HELIOS) of ibrutinib plus bendamustine and rituximab (BR) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)." LEUKEMIA & LYMPHOMA , vol.61, pp.106-108.

@article{article, author={Graeme Fraser Et Al. }, title={Final 5-year updated results from a phase 3 study (HELIOS) of ibrutinib plus bendamustine and rituximab (BR) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)}, journal={LEUKEMIA & LYMPHOMA}, year=2020, pages={106-108} }